No Data
No Data
China Securities Co., Ltd.: Q2 albumin batch issuance is the same as last year, and hepatitis B batch issuance has resumed growth.
The blood product industry is expected to maintain steady growth in the first half of 24H1. In the second half of the year, the industry is expected to continue the tight supply and demand pattern. The leading companies in the industry are expected to achieve continuous increase in plasma collection and profitability, and have more competitive advantages.
Express News | Corrected-Sinopharm Tech Holdings FY23 (Not FY24) Revenue HKD 42.8 Million
Express News | Sinopharm Tech Holdings FY Revenue HKD 42.8 Million
Is Sinopharm Group (HKG:1099) A Risky Investment?
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
No Data